Nicoletta Almirante

This inventor holds 27 USPTO granted patents and 11 published patent applications, plus 6 CIPO patents and 17 EPO patents, primarily in Ophthalmic Pharmacology. Top assignees: Nicox S.a., Merck Sharp + Dohme Corp., Nicox Science Ireland. Active years: 1994-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nicoletta Almirante. Retrieved from https://idiyas.com/inventor/nicoletta-almirante

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 27 (Patent Applications = 11)

% Patents Active = 51.9

CIPO Patents = 6 (Patent Applications = 8)

EPO Patents = 17 (Patent Applications = 21)

Average Co-Inventor Count = 3.6

ph-index = 3

Forward Citations = 25(Granted Patents)

Company Filing History:

Merck Sharp + Dohme Corp.

patents

5 out of 7

Nicox Science Ireland

patents

4. 3 out of 343

Sigma-Tau Industrie Farmaceutiche Riunite S.p.a.

where one patent can have more than one assignee

Years Active: 1994-2026

Loading Chart...

Areas of Expertise:

Glaucoma Treatment

Nitric Oxide Donors

Prostaglandin Analogs

Phosphodiesterase Inhibitors

Ophthalmic Compositions

Chronic Pain Drugs

Angiotensin Receptor Antagonists

Cicletanine Derivatives

ACE Inhibitor Derivatives

Nitrooxy Esters

Therapeutic Methods

Captopril Derivatives

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12728131 - Compositions for the treatment of glaucoma and ocular hypertension (2026-09-08),

2. 12709597 - PROCESS FOR THE PREPARATION OF A NITRIC OXIDE DONATING PROSTAGLANDIN ANALOGUE (2026-08-18),

3. 12642800 - Nitric oxide releasing phosphodiesterase type 5 inhibitor (2026-06-02),

4. 11980618 - Nitric oxide releasing phosphodiesterase type 5 inhibitor (2024-05-14),

5. 10988438 - Process for the preparation of a nitric oxide donating prostaglandin analogue (2021-04-27),

6. 10610509 - Combinations of prostaglandins and nitric oxide donors (2020-04-07),

7. 10280138 - Nitric oxide donating derivatives of fluprostenol (2019-05-07),

8. 10093696 - Nitric oxide donating carnosine compounds (2018-10-09),

9. 10047047 - Nitric oxide donating derivatives of latanoprost free acid (2018-08-14),

10. 9895335 - Ophthalmic compositions containing a nitric oxide donor (2018-02-20),

11. 9598349 - Quinone based nitric oxide donating compounds for ophthalmic use (2017-03-21),

12. 9446015 - Quinone based nitric oxide donating compounds for ophthalmic use (2016-09-20),

13. 9266820 - Nitric oxide donor compounds (2016-02-23),

14. 8367711 - Angiotensin II receptor antagonists (2013-02-05),

15. 8252825 - Angiotensin II receptor antagonists (2012-08-28),

Title: Innovations in Pharmacology: The Contributions of Nicoletta Almirante

Introduction

Nicoletta Almirante is a prominent inventor based in Milan, Italy, with an impressive portfolio of 24 patents. Her groundbreaking work primarily focuses on pharmacological innovations, specifically in the development of nitric oxide-releasing compounds, which hold significant therapeutic potential.

Latest Patents

Almirante's recent inventions include a nitric oxide-releasing phosphodiesterase type 5 inhibitor. This particular innovation relates to various forms and pharmacologically acceptable salts that enhance treatment efficacy. Another notable patent is for a process that prepares a nitric oxide donating prostaglandin analogue. This invention details the chemical synthesis of a specific ester compound through a method involving boronate protection and subsequent deprotection, showcasing her advanced knowledge in chemical processes.

Career Highlights

Throughout her career, Nicoletta Almirante has made significant contributions while being associated with renowned companies such as Nicox S.A. and Merck Sharp & Dohme Corporation. Her experience in these organizations has allowed her to refine her expertise and impact the pharmaceutical landscape extensively.

Collaborations

Almirante has also collaborated with notable peers in her field, including Laura Storoni and Ennio Ongini. These collaborations have fostered an enriching environment for research and innovation, driving forward the development of new treatments and technologies.

Conclusion

In summary, Nicoletta Almirante's contributions to the field of pharmacology through her numerous patents and collaborations underline her role as a significant innovator. Her work not only reflects her personal achievements but also paves the way for future advancements in therapeutic treatments that leverage nitric oxide and phosphodiesterase inhibition.

Profile summary based on public USPTO records.